Compare AGNC Investment Corp (AGNC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGNC Investment Corp vs Recursion Pharmaceuticals Inc — how do they compare? AGNC Investment Corp trades at $10.92 (market cap $12.91B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.81B). The key difference: AGNC Investment Corp is far larger — about 7.1× Recursion Pharmaceuticals Inc's market cap, and AGNC Investment Corp pays a 13.22% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AGNC | RXRX | |
|---|---|---|
Market Cap | $12.91B | $1.81B |
Sector | Financials | Health |
52-Week High | $12.17 | $6.79 |
52-Week Low | $9.46 | $2.84 |
Dividend Yield | 13.22% | — |
Enterprise Value | — | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
